Products for Research Use Only

Tiludronate-d5 (sodium)

CAT: 0804-HY-A0213ASSize: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-A0213ASSize:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Tiludronate-d5 (sodium) mis the deuterium labeled Tiludronate disodium. Tiludronate (Tiludronic Acid) disodium, an orally active bisphosphonate, can act an osteoregulator. Tiludronate is used for the research of the metabolic bone disorders. Tiludronate is a potent inhibitor of the osteoclast vacuolar H (+) -ATPase. Antiresorptive and anti-inflammatory properties[1][2][3][4].
Product Name Alternative
Tiludronic acid-d5 (sodium)
UNSPSC
12352005
Target
Isotope-Labeled Compounds; Proton Pump
Type
Isotope-Labeled Compounds
Related Pathways
Membrane Transporter/Ion Channel; Others
Field of Research
Inflammation/Immunology
Solubility
10 mM in DMSO
Smiles
O=P(C(P(O)(O[Na])=O)([2H])SC1=C([2H])C([2H])=C(C([2H])=C1[2H])Cl)(O[Na])O
Molecular Formula
C7H2D5ClNa2O6P2S
Molecular Weight
367.60
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Reginster JY, et al. Prevention of postmenopausal bone loss by tiludronate. Lancet. 1989 Dec 23-30;2 (8678-8679) :1469-71.|[3]Nunes NLT, et al. Effects of local administration of tiludronic acid on experimental periodontitis in diabetic rats. J Periodontol. 2018 Jan;89 (1) :105-116.|[4]Bonjour JP, et al. Tiludronate: bone pharmacology and safety. Bone. 1995;17 (5 Suppl) :473S-477S.|[5]David P, et al. The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H (+) -ATPase. J Bone Miner Res. 1996;11 (10) :1498-1507.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported